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Anaplastic Thyroid Carcinoma Arising From a
Calcified Thyroid Mass
A 68-year-old female presented for follow-up of a dense cal-
cifiedmass in the right thyroidwith a 3-year history. Anultrasound
(US) of the affected thyroid demonstrated a newly-developed hy-
poechoic area (Fig 1, arrows) at the low portion of the calcified
thyroid mass with multiple cervical lymphadenopathies (Fig 2) on
the right side. Three years prior, a neck US incidentally detected a
dense calcified mass in the right thyroid (Fig 3, arrows) without
evidence of pathologic lymphadenopathy. At that time, the cyto-
logic result of the calcified mass obtained using US-guided fine-
needle aspiration biopsy was nondiagnostic. At the most recent
follow-up, however, fine-needle aspiration biopsy of the newly-
developed hypoechoic area revealed papillary carcinoma. Subse-
quent total thyroidectomy with bilateral neck dissection was
performed. The specimen was an ill-defined lesion showing thick
irregular fibrosis (blue arrows) and calcifications (yellow arrows)
with a conventional papillary carcinoma area (black arrows) and
solid infiltrative area (Fig 4; 12.5). The solid infiltrative area
revealed highly atypical cells with polygonal or spindle and poly-
morphic cytoplasm and bizarre nuclei with prominent eosino-
philic nucleoli (Fig 5;200), suggesting anaplastic transformation.
After 3 months, the patient complained of palpable neck nodes.
The patient underwent fluorodeoxyglucose positron emission to-
mography/computed tomography to evaluate themetastasis.Mul-
tiple hypermetabolic lesions were detected on the lungs, heart,
neck, liver, and in the skeletal systems (Fig 6, arrows) on positron
emission tomography/computed tomography. She died of an up-
per respiratory infection 6 months after the operation.
Though anaplastic thyroid carcinomas account for only 1.6% of
primary malignant thyroid neoplasms,1 they are the most aggressive
malignancies known and have a poor prognosis and clinical
outcome.2-5 An anaplastic thyroid carcinoma is usually fatal with a
median survival of 3 to 9months, and only 10% to 15% of patients
survive 2 years. It is characterized by a rapid rate of local growth
and a high propensity for metastasis at initial presentation and
during its accelerated course.6 The rapidly fatal disease course that
is commonly observed in individuals diagnosed with anaplastic
thyroid cancer is in dramatic contrast to the excellent prognosis of
individuals diagnosed with differentiated thyroid cancer. An ana-
plastic thyroid carcinoma may arise in some cases from pre-
existing differentiated thyroid cancer.7 Anaplastic transformation
or the intratumoral evolution of anaplastic carcinoma from pre-
existing differentiated thyroid cancer has become a well-accepted
process, despite a limited understanding of its underlying mecha-
nisms.4,6 It can be considered a part of the natural history of an
untreated differentiated thyroid carcinoma. Fine-needle aspiration
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biopsy is the gold standard for diagnosis of a thyroid nodule. It has
a sensitivity of 71% to 93% and a specificity of 96%.7,8 However,
FNAC has a false negative rate of 11% to 25%, and 5% to 30% of
results were unsatisfactory or nondiagnostic.9,10 In our case, the
initial US-guided fine-needle aspiration biopsy revealed a nondi-
agnostic result. The clinician opted for a strategy of only observing
the mass until any change occurred. After 3 years of follow-up
investigation, the radiologist found a new soft tissue portion at the
inferior margin of the calcified mass. Finally, papillary carcinoma
was confirmed when US-guided needle aspiration biopsy was per-
formed by targeting the soft tissue component. Cytology of the
newly-developed soft tissue area arising from the long-standing
calcified mass was the key to diagnosis of this case. In our case, the
dense calcifiedmass did not change for 3 years. Although the calcified
thyroid mass was not confirmed as malignancy at the initial exam-
ination, the mass might have been a well-differentiated papillary
thyroid carcinoma. Anaplastic transformation, as a stage of thyroid
tumorigenesis, may develop from this long-standing well-
differentiated papillary carcinoma. In summary, an anaplastic thy-
roid carcinoma is a rare but very aggressive malignancy, and it can
evolve from a pre-existing well-differentiated papillary thyroid
carcinoma as a coarse calcified mass. Therefore, when new soft
tissue mass from a long-stable calcified thyroid mass is detected, a
prompt cytologic examination should be performed.
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Capecitabine-Induced Coronary Vasospasm
A 38-year-old woman with a history of hyperlipidemia and
breast cancer was hospitalized after undergoing an exercise stress
echocardiogram, which was markedly positive for ischemia. The
patient reported a strong family history of premature coronary
artery disease (CAD). She denied smoking and admitted to social
use of alcohol. Five years before the current events, ductal carci-
noma in situ was treated with lumpectomy, radiation therapy, and
chemotherapy with cyclophosphamide, paclitaxel, and doxorubi-
cin (a total dose of 240 mg/m2), which she tolerated without any
apparent cardiac toxicity. Two months prior to the stress test, a
recurrence of cancer in the lumpectomy bed was detected. She
underwent bilateral mastectomy with reconstruction, and adju-
vant oral capecitabine therapy was initiated at 3500mg daily. A few
days after beginning capecitabine, she noted dyspnea, lightheaded-
ness, and palpitationswithmild exertion, andwas no longer able to
tolerate her usual high-intensity workouts. She was referred for an
echocardiographic stress test. Her resting electrocardiogram
(ECG) was normal (Fig 1A). The resting ECG (Fig 1: Apical four-
chamber view of the left ventricle; 1B, diastole; and 1C, systole)
demonstrated normal cardiac function with left ventricular ejec-
tion fraction of 64%. The patient exercised on a treadmill using the
Bruce Protocol for 5 minutes and 18 seconds attaining a peak
workload of seven metabolic equivalent units (METs). The heart
rate quickly rose from 62 to 171 (93% predicted heart rate). She
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